Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.63 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27790018 | 0.87 | CDC7 (0.65) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1222603 | 0.85 | ALDH1A1 (0.72) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10853403 | 0.85 | CDC7 (0.71) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10848656 | 0.84 | CDC7 (0.61) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13788324 | 0.84 | CDC7 (0.66) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12571425 | 0.83 | NPC1 (0.47) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5041568 | 0.82 | SMN1; SMN2 (0.54) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1421843 | 0.81 | MKNK1 (0.62) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4283912 | 0.81 | HCAR2 (0.55) | CDC7DBF4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16703334 | 0.81 | PTPN11 (0.59) | CDC7DBF4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3877384-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-09-15 | — | — | EP | disclosed |
| CN-112969698-A | Chemical compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| EP-3468971-B1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3468971-A1 | NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2019-04-17 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6140504-A | Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6080767-A | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | CDC7 3467/4885DBF4 2198/4885NPC1 3330/4885 |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | CDC7 893/4885DBF4 4312/4885NPC1 406/4885 |
| US-20190144449-A1 | (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, BCL2, CCNK | CDC7 1688/4885DBF4 4300/4885NPC1 1133/4885 |
| US-10654849-B2 | (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CCNK | CDC7 1688/4885DBF4 4300/4885NPC1 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.